ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1674

Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis

Silvia Piantoni1, Enrico Colombo1, Angela Tincani1, Paolo Airò2 and Mirko Scarsi3, 1Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical immunology Unit, Spedali Civili of Brescia, Brescia, Italy, 3Internal Medicine Unit, Esine Vallecamonica Hospital, ASL Vallecamonica-Sebino, Esine, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Abatacept and rheumatoid arthritis (RA), T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The prediction of a stable treatment for rheumatoid arthritis (RA) is one of the targets of clinical research in rheumatology. However, only few biomarkers were successfully described as predictors of retention in therapy with biological agents. The aim of this paper was to investigate whether T-cell characterization might be used as predictor of abatacept (ABA) treatment continuation.

Methods:

Data are expressed as median (10th-90thpercentile), if not otherwise specified. Seventy-one consecutive RA patients treated with ABA were prospectively followed (female: 80%; age: 54 (40-71) years; disease duration: 7 (1-19) years; rheumatoid factor positivity: 81%; anti-cyclic citrullinated peptide (ACPA) positivity: 83%; DAS-28 (CRP): 5.1 (3.9-6.5); number of previous disease-modifying antirheumatic drugs: 3 (1-5); numbers of previous biological treatments: 2 (0-3), ABA as first line biological treatment: n=17).

T-cell characterization was performed by multi-color flow-cytometry (Navios, Beckman-Coulter).

Results:

At the end of our investigation, 28 patients discontinued ABA after 8 (4-16) months (18 for inefficacy; 5 for adverse events; 5 for other reasons) and 43 patients were still in therapy after 31 (13-62) months. In patients that maintained the treatment we observed: a lower proportion of smokers (25.6% vs 51.9%; p=0.03); a not significant lower proportion of  ACPA positivity (76% vs 89.5%; p=0.13); a higher proportion of CD8+ terminally differentiated effector memory (TDEM) T-cells at baseline (38.7 (20.7-55.9) vs 22.0 (7.8-39.2) % of CD8+ T-cells; p=0.002).  Other demographic, clinical and laboratory parameters were not different. Logistic multivariate analysis showed that only the proportion of CD8+TDEM T-cells was an independent predictive factor of high retention rate (OR (95% IC)=6.2 (1.2 to 30.8), p=0.026).

The ROC analysis showed a significant performance of this biomarker for prediction of persistence in therapy (using a cut-off of 30.6%: AUC: 0.760+0.07; p=0.002). patients with a high proportion of CD8+TDEM had a higher probability of continuing the treatment for a longer period of time (Mantel-Cox test: p<0.01). The positive and the negative predictive value of this test for treatment continuation were 83.3% and 65.0% respectively.

Conclusion:

T-cell characterization for identification of TDEM CD8+ T-cells might be a useful test to predict persistence in therapy with ABA.  It can be speculated that a high TDEM CD8+ T cell percentage might be a marker of previous repeated T-cell activation, identifying a subset of patients in which the CD28 costimulation blockade with ABA may be particularly efficacious.


Disclosure: S. Piantoni, None; E. Colombo, None; A. Tincani, None; P. Airò, None; M. Scarsi, None.

To cite this abstract in AMA style:

Piantoni S, Colombo E, Tincani A, Airò P, Scarsi M. Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/predictive-factors-of-persistence-in-therapy-with-abatacept-in-patients-with-rheumatoid-arthritis/. Accessed March 23, 2023.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-factors-of-persistence-in-therapy-with-abatacept-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences